Mutations in RAS are the most recognized oncogenic drivers across cancers, and offer an opportunity for cells to recover fitness deficits induced by JAK inhibition by employing non-JAK/STAT-mediated signaling pathways instead [89]. The gene discussed is SOAT1; the disease is cancer.